The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1
Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental strains are, however, mostly based on laboratory reference strains, which may possess a compromised cy...
Main Authors: | Kiira Kalke, Julius Orpana, Tuomas Lasanen, Olaya Esparta, Liisa M. Lund, Fanny Frejborg, Tytti Vuorinen, Henrik Paavilainen, Veijo Hukkanen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/14/6/1290 |
Similar Items
-
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
by: Norah Aldrak, et al.
Published: (2021-06-01) -
Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study
by: Ravi N. Samy, et al.
Published: (2019-10-01) -
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells
by: Kimia Kardani, et al.
Published: (2023-05-01) -
Development and Preliminary Application of a Droplet Digital PCR Assay for Quantifying the Oncolytic Herpes Simplex Virus Type 1 in the Clinical-Grade Production
by: Miaomiao Guo, et al.
Published: (2023-01-01) -
Current landscape in antiviral drug development against herpes simplex virus infections
by: Fanny Frejborg, et al.
Published: (2022-12-01)